Novavax Inc (NVAX)
8.05
-0.01
(-0.12%)
USD |
NASDAQ |
Nov 21, 16:00
7.95
-0.10
(-1.24%)
After-Hours: 20:00
Novavax Enterprise Value: 550.83M for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 550.83M |
| November 19, 2024 | 541.21M |
| November 18, 2024 | 513.98M |
| November 15, 2024 | 432.29M |
| November 14, 2024 | 416.27M |
| November 13, 2024 | 503.57M |
| November 12, 2024 | 614.90M |
| November 11, 2024 | 703.00M |
| November 08, 2024 | 686.98M |
| November 07, 2024 | 730.23M |
| November 06, 2024 | 694.99M |
| November 05, 2024 | 771.88M |
| November 04, 2024 | 720.62M |
| November 01, 2024 | 757.46M |
| October 31, 2024 | 799.11M |
| October 30, 2024 | 835.59M |
| October 29, 2024 | 872.43M |
| October 28, 2024 | 901.25M |
| October 25, 2024 | 820.38M |
| October 24, 2024 | 848.40M |
| October 23, 2024 | 861.22M |
| October 22, 2024 | 880.43M |
| October 21, 2024 | 883.64M |
| October 18, 2024 | 890.04M |
| October 17, 2024 | 917.27M |
| Date | Value |
|---|---|
| October 16, 2024 | 885.24M |
| October 15, 2024 | 1.278B |
| October 14, 2024 | 1.281B |
| October 11, 2024 | 1.266B |
| October 10, 2024 | 1.326B |
| October 09, 2024 | 1.290B |
| October 08, 2024 | 1.348B |
| October 07, 2024 | 1.345B |
| October 04, 2024 | 1.439B |
| October 03, 2024 | 1.569B |
| October 02, 2024 | 1.611B |
| October 01, 2024 | 1.233B |
| September 30, 2024 | 1.282B |
| September 27, 2024 | 1.248B |
| September 26, 2024 | 1.064B |
| September 25, 2024 | 1.047B |
| September 24, 2024 | 1.247B |
| September 23, 2024 | 1.168B |
| September 20, 2024 | 1.186B |
| September 19, 2024 | 1.124B |
| September 18, 2024 | 1.130B |
| September 17, 2024 | 1.189B |
| September 16, 2024 | 1.232B |
| September 13, 2024 | 1.298B |
| September 12, 2024 | 1.028B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-349.18M
Minimum
Mar 23 2023
22.60B
Maximum
Feb 08 2021
4.202B
Average
1.479B
Median
Enterprise Value Benchmarks
| Pfizer Inc | 198.27B |
| Moderna Inc | 7.348B |
| Inovio Pharmaceuticals Inc | 18.81M |
| Baxter International Inc | 28.25B |
| Halozyme Therapeutics Inc | 6.660B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -121.30M |
| Revenue (Quarterly) | 84.51M |
| Total Expenses (Quarterly) | 218.53M |
| EPS Diluted (Quarterly) | -0.76 |
| Gross Profit Margin (Quarterly) | 28.27% |
| Profit Margin (Quarterly) | -143.5% |
| Earnings Yield | -28.45% |
| Normalized Earnings Yield | -28.45 |